Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05775848 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)
A Phase 3 study of Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), sponsored by ML Bio Solutions.
- Active
- Registry status
- Phase 3
- Development phase
- 81
- Enrollment target
- 20
- Study locations
NCT05775848: Active Phase 3 study of Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), sponsored by ML Bio Solutions.
NCT05775848 is a Phase 3 study of Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) that is active but no longer recruiting, run by ML Bio Solutions. The registered enrollment target is 81 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05775848, a Phase 3 study of Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I), is active but no longer recruiting, sponsored by ML Bio Solutions.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 81 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients based upon the established epidemiology of the disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BBP-418 (ribitol)
Study Locations (20)
Other
- Rigshospitalet, Neuromuscular Clinic and Research Unit - Copenhagen
- Charité Universitätsmedizin Berlin and Max Delbrück Center - Berlin
- IRCCS Ca' Granda Ospedale - Milan
- Leiden University Medical Center - Leiden
- Universitetssykehuset Nord-Norge, Department of Neurology - Tromsø
- Great Ormond Street Hospital for Children - London
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
- University of Pennsylvania - Philadelphia
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- University of California Irvine - Irvine
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- University of Florida - Gainsville
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What the registry record for NCT05775848 still lists
NCT05775848 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05775848 names 20 study sites across 14 states, led by Other, Pennsylvania, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05775848 about?
NCT05775848 is a clinical study titled "Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)". This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the significant majority of existing diagnosed patients ...
What is the current status of trial NCT05775848?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 2023-05-31. Estimated completion is 2027-07.
What conditions does trial NCT05775848 study?
This clinical trial studies the following conditions: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I).
What interventions are being tested in trial NCT05775848?
The interventions under investigation include: Placebo (OTHER), BBP-418 (ribitol) (DRUG).
Who is sponsoring clinical trial NCT05775848?
This trial is sponsored by ML Bio Solutions, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05775848 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05775848's enrollment target sits among peer trials
81 1753rd of 2000 higher than 246 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI